In cancer patients undergoing systemic therapy, elevated baseline levels of BDNF have been associated with clinical response and improved OS in patients with multiple myeloma treated with bortezomib, and/or thalidomide-based chemotherapy [53], but with poorer PFS in patients with pancreatic adenocarcinoma receiving FOLFIRINOX neoadjuvant chemotherapy regimen [101]. This evidence concerns the gene BDNF and plasma cell myeloma.